Children's toxicology from bench to bed - Liver Injury (1)

Drug-induced metabolic disturbance - Toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Congenital disorders of metabolism show a wide spectrum of symptoms as a consequence of impairment of a certain metabolic pathway by mutated enzymes resulting in abnormal accumulation of enzyme substrates, deficiency of expected products, and abnormal burden to collateral metabolic pathways, etc. However, in some occasions, depending on which pathway up to what degree of disturbance, it can be asymptomatic until a certain kind of burden is placed on to the patient. Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. However, when the patients are treated with 5-fluorouracil, a pyrimidine analogue anticancer drug, lethal side-effects can be seen even in asymptomatic patients. Some oral cephem antibiotics have pivalic acid side chain to increase absorption rate at intestine. These antibiotics degrade into active antibiotics and pivalic acid at the intestinal wall. This pivalic acid is carnitine-conjugated and excreted into urine. Carnitine acts as a carrier of long chain fatty acid to mitochondria and to beta-oxidation, thus an important molecule for energy production by beta-oxidation and maintenance of mitochondrial function. Because of this, long term administration of such antibiotics could induce depletion of carnitine from the body and lead to low ketotic hypoglycemia, convulsion and consciousness disturbance. This paper reports some possible serious side effects closely linked to drug metabolism.

Original languageEnglish
JournalJournal of Toxicological Sciences
Volume34
Issue number2 SPEC. ISS.
DOIs
Publication statusPublished - 30-07-2009
Externally publishedYes

Fingerprint

Chemical and Drug Induced Liver Injury
Carnitine
Metabolism
Fluorouracil
Liver
Toxicology
Toxicity
Anti-Bacterial Agents
dihydropyrimidinase
Metabolic Networks and Pathways
Pharmaceutical Preparations
Seizures
Enzymes
Dihydrouracil Dehydrogenase (NADP)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oxidation
Mitochondria
Autistic Disorder
Drug-Related Side Effects and Adverse Reactions
Consciousness

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

@article{13485f6827214d77b8fbc74b6e4e272d,
title = "Children's toxicology from bench to bed - Liver Injury (1): Drug-induced metabolic disturbance - Toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism",
abstract = "Congenital disorders of metabolism show a wide spectrum of symptoms as a consequence of impairment of a certain metabolic pathway by mutated enzymes resulting in abnormal accumulation of enzyme substrates, deficiency of expected products, and abnormal burden to collateral metabolic pathways, etc. However, in some occasions, depending on which pathway up to what degree of disturbance, it can be asymptomatic until a certain kind of burden is placed on to the patient. Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. However, when the patients are treated with 5-fluorouracil, a pyrimidine analogue anticancer drug, lethal side-effects can be seen even in asymptomatic patients. Some oral cephem antibiotics have pivalic acid side chain to increase absorption rate at intestine. These antibiotics degrade into active antibiotics and pivalic acid at the intestinal wall. This pivalic acid is carnitine-conjugated and excreted into urine. Carnitine acts as a carrier of long chain fatty acid to mitochondria and to beta-oxidation, thus an important molecule for energy production by beta-oxidation and maintenance of mitochondrial function. Because of this, long term administration of such antibiotics could induce depletion of carnitine from the body and lead to low ketotic hypoglycemia, convulsion and consciousness disturbance. This paper reports some possible serious side effects closely linked to drug metabolism.",
author = "Tetsuya Ito",
year = "2009",
month = "7",
day = "30",
doi = "10.2131/jts.34.SP217",
language = "English",
volume = "34",
journal = "Journal of Toxicological Sciences",
issn = "0388-1350",
publisher = "Japanese Society of Toxicological Sciences",
number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - Children's toxicology from bench to bed - Liver Injury (1)

T2 - Drug-induced metabolic disturbance - Toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism

AU - Ito, Tetsuya

PY - 2009/7/30

Y1 - 2009/7/30

N2 - Congenital disorders of metabolism show a wide spectrum of symptoms as a consequence of impairment of a certain metabolic pathway by mutated enzymes resulting in abnormal accumulation of enzyme substrates, deficiency of expected products, and abnormal burden to collateral metabolic pathways, etc. However, in some occasions, depending on which pathway up to what degree of disturbance, it can be asymptomatic until a certain kind of burden is placed on to the patient. Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. However, when the patients are treated with 5-fluorouracil, a pyrimidine analogue anticancer drug, lethal side-effects can be seen even in asymptomatic patients. Some oral cephem antibiotics have pivalic acid side chain to increase absorption rate at intestine. These antibiotics degrade into active antibiotics and pivalic acid at the intestinal wall. This pivalic acid is carnitine-conjugated and excreted into urine. Carnitine acts as a carrier of long chain fatty acid to mitochondria and to beta-oxidation, thus an important molecule for energy production by beta-oxidation and maintenance of mitochondrial function. Because of this, long term administration of such antibiotics could induce depletion of carnitine from the body and lead to low ketotic hypoglycemia, convulsion and consciousness disturbance. This paper reports some possible serious side effects closely linked to drug metabolism.

AB - Congenital disorders of metabolism show a wide spectrum of symptoms as a consequence of impairment of a certain metabolic pathway by mutated enzymes resulting in abnormal accumulation of enzyme substrates, deficiency of expected products, and abnormal burden to collateral metabolic pathways, etc. However, in some occasions, depending on which pathway up to what degree of disturbance, it can be asymptomatic until a certain kind of burden is placed on to the patient. Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. However, when the patients are treated with 5-fluorouracil, a pyrimidine analogue anticancer drug, lethal side-effects can be seen even in asymptomatic patients. Some oral cephem antibiotics have pivalic acid side chain to increase absorption rate at intestine. These antibiotics degrade into active antibiotics and pivalic acid at the intestinal wall. This pivalic acid is carnitine-conjugated and excreted into urine. Carnitine acts as a carrier of long chain fatty acid to mitochondria and to beta-oxidation, thus an important molecule for energy production by beta-oxidation and maintenance of mitochondrial function. Because of this, long term administration of such antibiotics could induce depletion of carnitine from the body and lead to low ketotic hypoglycemia, convulsion and consciousness disturbance. This paper reports some possible serious side effects closely linked to drug metabolism.

UR - http://www.scopus.com/inward/record.url?scp=67651171546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651171546&partnerID=8YFLogxK

U2 - 10.2131/jts.34.SP217

DO - 10.2131/jts.34.SP217

M3 - Article

VL - 34

JO - Journal of Toxicological Sciences

JF - Journal of Toxicological Sciences

SN - 0388-1350

IS - 2 SPEC. ISS.

ER -